|17.71||+0.6200||+3.63%||Vol 304.95K||1Y Perf 649.36%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||34.80||Analyst Rating||Strong Buy 1.40|
|Potential %||96.50||Finscreener Ranking||★★★+ 51.19|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 55.95|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 53.10|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||54.96||Earnings Rating||Strong Buy|
|Market Cap||1.08B||Earnings Date||3rd Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2021|
|Estimated EPS Next Report||-0.27|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||471.41K|
|Avg. Monthly Volume||381.78K|
|Avg. Quarterly Volume||566.75K|
Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 17.71 per share at the end of the most recent trading day (a 3.63% change compared to the prior day closing price) with a volume of 305.38K shares and market capitalization of 1.08B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.
The one-year performance of Aclaris Therapeutics Inc. stock is 649.36%, while year-to-date (YTD) performance is 173.72%. ACRS stock has a five-year performance of -27.71%. Its 52-week range is between 2.25 and 30.38, which gives ACRS stock a 52-week price range ratio of 54.96%
Aclaris Therapeutics Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 4.62, a price-to-sale (PS) ratio of 164.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.46%, a ROC of -46.28% and a ROE of -49.49%. The company’s profit margin is -%, its EBITDA margin is -760.30%, and its revenue ttm is $6.63 Million , which makes it $0.11 revenue per share.
Of the last four earnings reports from Aclaris Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is 03rd Nov 2021.
The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Strong Buy (1.4), with a target price of $34.8, which is +96.50% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aclaris Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 30.32, ATR14 : 1.04, CCI20 : 69.86, Chaikin Money Flow : 0.09, MACD : 0.67, Money Flow Index : 79.58, ROC : 12.87, RSI : 62.36, STOCH (14,3) : 76.03, STOCH RSI : 0.55, UO : 48.44, Williams %R : -23.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $268 298), David N. Gordon (Option Excercise at a value of $0), David N. Gordon (Sold 2 631 shares of value $44 675 ), Frank Ruffo (Option Excercise at a value of $0), Frank Ruffo (Sold 87 339 shares of value $2 310 106 ), Kamil Ali-Jackson (Option Excercise at a value of $479 700), Kamil Ali-Jackson (Sold 45 000 shares of value $1 083 718 ), Neal Walker (Option Excercise at a value of $0), Neal Walker (Sold 30 000 shares of value $805 239 )
Mon, 09 Aug 2021 10:26 GMT Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.